IRulya Therapeutics Inc. (IRLA) Stock Price & Analysis
IRulya Therapeutics Inc. (IRLA) closed at USD 33.23 on Thursday, October 15, 2026, up 10.77% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 30; the Oct 15, 2026 session ranged USD 28.99–33.71 on volume of 8,961 shares. Market capitalization is $33.80M, with a 52-week range of USD 15.1–910 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/IRLA.md
Key facts (IRLA)
- Analysts: Buy (mean 1.89 on a 1–5 scale) (9 analysts), mean target USD 75 (range 65–98).
- Total return with dividends: 1Y -91.4% vs S&P 500 +18.1%; 5Y -99.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -1.2, revenue estimate $0K.
Analysts (IRLA)
Consensus Buy (mean 1.89 on a 1–5 scale), 9 analysts; mean target USD 75 (low 65, high 98).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-09 | Raymond James | Initiated | Outperform | $72 |
| 2026-09-24 | Rodman & Renshaw | Initiated | Buy | $70 |
| 2026-09-22 | Citizens | Upgrade | Market Perform → Market Outperform | $77 |
| 2026-08-18 | Cantor Fitzgerald | Reiterated | Overweight | $70 |
| 2026-07-29 | Oppenheimer | Initiated | Outperform | $82 |
| 2026-06-24 | Leerink Partners | Initiated | Outperform | $4 |
| 2026-06-23 | Cantor Fitzgerald | Initiated | Overweight | $4 |
Total return (dividends reinvested) (IRLA)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -91.4% | -99.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -91.5% | -69.4% |
| Volatility (annualized) | 330.4% | 170.1% |
| Max drawdown | -98.2% (Dec 2025→Mar 2026) | -99.9% (Oct 2021→Mar 2026) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 33.23 |
|---|---|
| Change | ▲ 10.77% (up) |
| Previous Close | USD 30 |
| Open | USD 28.99 |
| Day Range | USD 28.99 – 33.71 |
| 52-Week Range | USD 15.1 – 910 |
| Volume | 8,961 shares |
| Market Cap | $33.80M |
| Exchange | NCM |
Technical Analysis (IRLA)
Nexqual's technical model rates IRLA "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 55.72 (neutral) |
| vs SMA50 | Above (USD 30.79) |
| MACD | 0.28 (positive) |
Analyst Ratings (IRLA)
Wall Street analysts rate IRLA "Buy" based on 9 analysts, with a mean price target of USD 75 (range USD 65–98), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 75 |
| High Target | USD 98 |
| Low Target | USD 65 |
| Buy / Hold / Sell | 8 / 1 / 0 |
Earnings (IRLA)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -1.2 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -12.15 vs est -12.39 ▲ beat |
| 2026-03-31 | USD 57.6 vs est -52 ▲ beat |
| 2025-12-31 | USD -152 vs est -45 ▼ miss |
| 2025-09-30 | USD -50 vs est -44.5 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (IRLA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -153.84% |
| Current Ratio | 14.52 |
| Total Cash | $115.98M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (IRLA)
Nexqual rates IRulya Therapeutics Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $116M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$47M (TTM) |
| Efficiency | Critical — ROE -154%, ROA -31.5% |
Ownership (IRLA)
| Insider Ownership | +0.27% |
|---|---|
| Institutional Ownership | +3.24% |
| Shares Outstanding | 1.02M |
| Float | 679,683 |
| Short % of Float | +5.91% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (IRLA)
IRulya Therapeutics Inc. is led by Brigette Roberts (age 50), CEO, Principal Executive Officer & Director, per Nexqual as of October 16, 2026 at 05:19 UTC.
| CEO, Principal Executive Officer & Director | Brigette Roberts (age 50) |
|---|---|
| Chief Operating Officer | Keith R. Fandrick (age 46) |
| Chief Scientific Officer | Guenter R. Janhofer |
Major Backers & Investors (IRLA)
Notable institutional backers of IRulya Therapeutics Inc. include Ikarian Capital, LLC, Millennium Management, Balyasny Asset Management LP, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ikarian Capital, LLC | 7.39% |
| Millennium Management | 7.24% |
| Balyasny Asset Management LP | 7.15% |
| Squadron Capital Management LLC | 4.13% |
| Shay Capital LLC | 1.79% |
| Boothbay Fund Management, LLC | 1.42% |
| Jane Street Group, LLC | 1.29% |
| Fidelity | 0.86% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.46% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt